183 related articles for article (PubMed ID: 37614557)
1. Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis.
Dahmani H; Fradi I; Achour L; Toumi M;
J Mark Access Health Policy; 2023; 11(1):2244304. PubMed ID: 37614557
[TBL] [Abstract][Full Text] [Related]
2. Pricing of in-patent pharmaceuticals in the Middle East and North Africa: Is external reference pricing implemented optimally?
Kanavos P; Kamphuis BW; Fontrier AM; Colville Parkin G; Saleh S; Akhras KS
Health Policy; 2020 Dec; 124(12):1297-1309. PubMed ID: 32962876
[TBL] [Abstract][Full Text] [Related]
3. Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe.
Vončina L; Strbad T; Fürst J; Dimitrova M; Kamusheva M; Vila M; Mardare I; Hristova K; Harsanyi A; Atanasijević D; Banović I; Bobinac A
Appl Health Econ Health Policy; 2021 Nov; 19(6):915-927. PubMed ID: 34553334
[TBL] [Abstract][Full Text] [Related]
4. Methods for the comparative evaluation of pharmaceuticals.
Zentner A; Velasco-Garrido M; Busse R
GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
[TBL] [Abstract][Full Text] [Related]
5. External Reference Pricing for Pharmaceuticals-A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage.
Holtorf AP; Gialama F; Wijaya KE; Kaló Z
Value Health Reg Issues; 2019 Sep; 19():122-131. PubMed ID: 31416014
[TBL] [Abstract][Full Text] [Related]
6. Value added medicines: what value repurposed medicines might bring to society?
Toumi M; Rémuzat C
J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
[No Abstract] [Full Text] [Related]
7. Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review.
Kawalec P; Tesar T; Vostalova L; Draganic P; Manova M; Savova A; Petrova G; Rugaja Z; Männik A; Sowada C; Stawowczyk E; Harsanyi A; Inotai A; Turcu-Stiolica A; Gulbinovič J; Pilc A
Front Pharmacol; 2017; 8():892. PubMed ID: 29326583
[No Abstract] [Full Text] [Related]
8. Overview of external reference pricing systems in Europe.
Rémuzat C; Urbinati D; Mzoughi O; El Hammi E; Belgaied W; Toumi M
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123181
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries.
Atikeler EK; Özçelikay G
Springerplus; 2016; 5(1):1876. PubMed ID: 27833835
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
11. Policies and availability of orphan medicines in outpatient care in 24 European countries.
Sarnola K; Ahonen R; Martikainen JE; Timonen J
Eur J Clin Pharmacol; 2018 Jul; 74(7):895-902. PubMed ID: 29632962
[TBL] [Abstract][Full Text] [Related]
12. Cervical cancer in the Maghreb country (Morocco - Algeria - Tunisia) : epidemiological, clinical profile and control policy.
Yazghich I; Berraho M
Tunis Med; 2018; 96(10-11):647-657. PubMed ID: 30746657
[TBL] [Abstract][Full Text] [Related]
13. Population policies in the Maghreb.
Lapham RJ
Concerned Demogr; 1971 Mar; 2(4):36-44. PubMed ID: 12256255
[TBL] [Abstract][Full Text] [Related]
14. Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?
Vogler S; Salcher-Konrad M; Habimana K
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(8):867-878. PubMed ID: 37450611
[TBL] [Abstract][Full Text] [Related]
15. How does external reference pricing work in developing countries: evidence from Iran.
Babaie F; Motevalli MH; Mehralian G; Peiravian F; Yousefi N
Front Pharmacol; 2023; 14():1034229. PubMed ID: 37408767
[No Abstract] [Full Text] [Related]
16. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
Davidova J; Praznovcova L; Lundborg CS
Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
[TBL] [Abstract][Full Text] [Related]
17. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
18. The role of insurance policies in the drug pricing landscape.
Savova A; Manova M; Tachkov K; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):189-202. PubMed ID: 38064353
[TBL] [Abstract][Full Text] [Related]
19. Research cartography of implantable medical devices in the three Maghreb countries: A comparative study between Morocco, Algeria, and Tunisia.
Qouhafa M; Benaji B; Lebbar S; Marrakchi A; Soulaymani A; Nsiri B; Alaoui MHEY; Abdelrhani M; Azougagh M
Ann Pharm Fr; 2024 May; 82(3):522-530. PubMed ID: 38135036
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
